83-year-old Elisa Friel of Ocean Township Receives the 10,000 dose
Hackensack Meridian Jersey Shore University Medical Center administered its 10,000 dose of COVID-19 vaccine February 2 to 83-year-old Elisa Friel of Ocean Township.
Hackensack Meridian CDI and partners at the University of Michigan Demonstrate Better, Faster COVID-19 Antibody...
Better tool, methodology could mean better convalescent plasma
A more efficient and much faster method to assess high levels of neutralizing antibodies to COVID-19 could point the way to better understanding and treatment of the disease,
Jersey Shore University Medical Center Recognized Nationally as a Best Maternity Care Hospital by Newsweek
Hackensack Meridian Jersey Shore University Medical Center was named to Newsweek’s 2020 list of Best Maternity Care Hospitals.
Hackensack Meridian Health is pleased to announce the appointment of Daniel W. Varga, M.D., as chief physician executive.
Hackensack Meridian Health is pleased to announce the appointment of Amy Frieman, M.D., MBA, FAAHPM as chief wellness officer.
NJHA awards Hackensack Meridian Health Carrier Clinic for its efforts to promote and improve behavioral...
Hackensack Meridian Health Carrier Clinic was honored today with the New Jersey Hospital Association’s Health Education and Regional Trust Community Outreach Award for Behavioral Health/Resilience in recognition of Carrier’s ground-breaking efforts to increase awareness of and expand access to mental health and addiction services.
Less than half of patients with metastatic tumors have the recommended genomic profiling that forms the basis of precision oncology
Investigators at John Theurer Cancer Center (JTCC) at Hackensack University Medical Center in New Jersey are the first to report poor adherence to genomic profiling guidelines for four biomarkers of metastatic colorectal cancer used to predict response to therapy,
John Theurer Cancer Center Investigators Report Effectiveness of New Treatment for Refractory Multiple Myeloma
Triple-drug regimen shown to be superior to conventional treatment in major multicenter study presented at American Society of Hematology annual meeting
Investigators at John Theurer Cancer Center at Hackensack University Medical Center in New Jersey were part of the CANDOR global phase III clinical trial for patients with refractory (persistent) multiple myeloma.